Form 4: Ultragenyx CFO Sells Shares Under 10b5-1 Plan

Ultragenyx Pharmaceutical's Chief Financial Officer, Howard Horn, sold 3,061 shares of common stock for $23.56 per share as part of a pre-arranged trading plan.

Summary

• Howard Horn, the Chief Financial Officer of Ultragenyx Pharmaceutical Inc. (RARE), executed a sale of company common stock.
• The transaction involved the disposition of 3,061 shares of common stock.
• The shares were sold at a price of $23.56 per share.
• The total value of the shares sold was approximately $72,100.16.
• Following this transaction, Mr. Horn beneficially owns 88,935 shares of Ultragenyx common stock.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan, indicating it was pre-scheduled.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale can sometimes be a negative signal, the execution under a 10b5-1 plan suggests a pre-planned, routine transaction for personal financial management rather than a reaction to new company-specific information.

Positives

• The sale was executed under a Rule 10b5-1 trading plan, which suggests the transaction was pre-scheduled and not based on new, non-public information.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces management's direct equity stake in the company.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are common in the biotechnology and pharmaceutical sectors, often occurring as part of pre-arranged 10b5-1 plans for personal financial planning or diversification. While a sale reduces an executive's direct stake, the context of a 10b5-1 plan typically mitigates concerns about its implications for the company's immediate prospects.

Comparison to Industry Standards

• Insider sales under 10b5-1 plans are a standard practice across industries, including biotech, for executives to manage their personal finances and diversify holdings without being accused of trading on inside information. For example, executives at companies like Amgen or Gilead Sciences frequently execute similar pre-planned sales.
• The volume of shares sold (3,061 shares) represents a relatively small fraction of the CFO's total beneficial ownership (88,935 shares), which is typical for routine diversification rather than a significant divestment.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a slight negative, though the 10b5-1 plan mitigates concerns. The reduction in direct insider ownership is minimal relative to total holdings.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The insider sale by the CFO, while a reduction in direct ownership, was conducted under a pre-arranged 10b5-1 plan. This suggests a routine financial planning event rather than a signal of deteriorating company fundamentals. Given the context, this single transaction is unlikely to significantly alter the investment thesis for Ultragenyx Pharmaceutical, warranting a 'hold' recommendation based solely on this filing.

Keywords

Ultragenyx Pharmaceutical, RARE, Form 4, Insider Sale, Howard Horn, Chief Financial Officer, 10b5-1 Plan, Biotechnology, Pharmaceuticals, Stock Transaction